The Latest Breaking News from Merck

The Dow Jones rose Thursday after a surprise drop in jobless claims. Meta stock surged, but hot AI stock Mobileye crashed 30% on earnings.

Merck topped forecasts Thursday while Bristol Myers delivered a mixed performance. Merck stock swung to a gain while and BMY stock fell.

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.23%. U.S. stock indexes this morning are mixed. An increase...

Moderna stock crumbled Monday after updated results for its Merck-partnered cancer vaccine show a "longish and complex path" toward approval.

Google parent Alphabet sold off more than 3% after Samsung considered ditching the search engine.

Merck is acquiring Prometheus Bio in a well-timed $10.8 billion deal ahead of Keytruda's patent loss. The news sent RXDX stock flying Monday.

Morning Markets June S&P 500 futures (ESM2 3) this morning are up +0.02%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.03%. U.S. stock index futures this morning are mixed. An increase in M&A activity is positive for stocks after Merck said it would acquire Prometheus Biosciences for...

Stock futures edge higher with earnings, treasury yields in focus; Week Ahead: busy earnings week, housing data on deck; Prometheus Biosciences soars after $10.8 billion Merck takeover; Netflix 'Love is Blind' live event scrapped after user outage and Charles Schwab earnings up next as broker weathers bank sector storm.

Adding a personalized cancer vaccine to the blockbuster drug Keytruda kept more melanoma patients in remission than the immune therapy alone, co-developers Moderna Inc. and Merck & Co. said in their first detailed presentation of a key study.